Three years after centralized procurement reshaped China's orthopedic implant industry, domestic leaders reported a recovery in Q1 2025, with growth accelerating over the next two quarters. Major players recently disclosed Q3 2025 results, showing most achieved revenue and profit growth, particularly through overseas expansion becoming a new growth driver. This performance uplift is reflected in stock prices: by November 25, Beijing Chunlizhengda's A/H shares surged over 90% YTD, while Dabo Medical and Weigao Orthopedics gained 56.83% and 20.72% respectively. However, AK MEDICAL (01789), an early recovery leader post-procurement, lagged with just 17.23% YTD growth and now faces potential removal from the Stock Connect program.

**Delayed Rebound, Consolidating at Lows** H1 2025 saw AK MEDICAL's shares steadily climb with sector recovery, peaking at HK$7.24 on July 30 (up 53.72% YTD). However, prices plateaued before plunging nearly 14% on August 28 after interim results. While peers posted stellar H1 profit growth—Dabo Medical (+76.69%), Chunlizhengda (+44.85%), Weigao Orthopedics (+52.43%), and Sanyou Medical (+2083.64%)—AK MEDICAL managed only 15.34%. Notably, AK MEDICAL's H1 revenue grew 45% versus pre-procurement peaks, outperforming Weigao (-64%) and Sanyou (-52%), yet markets discounted this in valuations.

**Overseas Focus vs. Domestic Reliance** Global orthopedic device markets reached $62.22 billion in 2024 (5.3% CAGR projected to 2032), making overseas expansion critical as domestic growth plateaus. Chunlizhengda, with 40% H1 revenue from abroad, exemplifies this shift. AK MEDICAL derived just 18% from overseas—third among top players but trailing leaders significantly.

**Technical Weakness** August 28's sell-off (5.5M shares traded, BOLL bands expanding) signaled short-term downtrend. Subsequent consolidation saw BOLL bands narrowing by September 24, indicating range-bound trading until October 20. Recent "false breakouts" without volume support suggest poor timing for short-term entries.

**Stock Connect Survival Battle** Since August, AK MEDICAL has traded flat (0.36% gain, 23.1% volatility) as buyers accumulated shares near HK$6. With 78.57% overlap between 70%-90% cost concentrations,筹码高度集中 suggests limited near-term volatility—critical for maintaining its HK$6.35B average market cap (barely above the HK$6.12B Stock Connect threshold). Mainland investors via Stock Connect (holding 22.73% combined) have become key supporters, with China Investment (Shanghai-HK) emerging as the second-largest broker holder after two months of net buying.

At 19.51x P/E (9% below 1-year average), AK MEDICAL trades at a sector discount, presenting contrarian opportunities amid broader industry recovery—if it can defend its Stock Connect status by year-end.